Review of Pharmacotherapeutic Targets in Alzheimer’s Disease and Its Management Using Traditional Medicinal Plants

References

• Toodayan N. Professor Alois Alzheimer (1864–1915): lest we forget. J Clin Neurosci. 2016;31:47–55. doi:10.1016/j.jocn.2015.12.032
   PubMed Web of Science ®Google Scholar
• Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2019. Front Aging Neurosci. 2022;14:937486. doi:10.3389/fnagi.2022.937486
   PubMed Web of Science ®Google Scholar
• Thébaut C, Achille D, Preux P, Guerchet M. Costs of Dementia in Low-And Middle-Income Countries: a Systematic Review. J Alzh Dis. 2022;2022:1.
   Google Scholar
• Huo Z. The Disease Burden and Economic Cost of Dementia in an Asian Population. Hong Kong: The Chinese University of Hong Kong; 2021.
   Google Scholar
• Elfaki BA. Factors contributes to overweight and obesity among young adults; 2023.
   Google Scholar
• Ma Y, Ajnakina O, Steptoe A, Cadar D. Higher risk of dementia in English older individuals who are overweight or obese. Internat J Epidemiol. 2020;49(4):1353–1365. doi:10.1093/ije/dyaa099
   PubMed Web of Science ®Google Scholar
• Kabir MT, Shah MA, Alothaim AAS, Al-Ghamdi MS, Rahman MH. Neuroprotective effects of saponins on neurodegenerative diseases. In: Phytonutrients and Neurological Disorders. Elsevier; 2023:259–282.
   Google Scholar
• Selman A, Burns S, Reddy AP, Culberson J, Reddy PH. The role of obesity and diabetes in dementia. Internat J Molec Sci. 2022;23(16):9267. doi:10.3390/ijms23169267
   PubMed Web of Science ®Google Scholar
• Sathianathan R, Kantipudi SJ. The dementia epidemic: impact, prevention, and challenges for India. Indian J Psych. 2018;60(2):165. doi:10.4103/psychiatry.IndianJPsychiatry_261_18
   PubMed Web of Science ®Google Scholar
• Ravindranath V, Sundarakumar JS. Changing demography and the challenge of dementia in India. Nat Rev Neurol. 2021;17(12):747–758. doi:10.1038/s41582-021-00565-x
   PubMed Web of Science ®Google Scholar
• Binda A, Murano C, Rivolta I. Innovative therapies and nanomedicine applications for the treatment of Alzheimer’s disease: a state-of-The-art (2017–2020). Internat J Nanomed. 2020;15:6113–6135. doi:10.2147/IJN.S231480
   PubMed Web of Science ®Google Scholar
• Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harbor Perspect Med. 2012;2(5):a006148–a006148. doi:10.1101/cshperspect.a006148
   PubMed Web of Science ®Google Scholar
• Zubenko GS, Zubenko WN, McPherson S, et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer’s disease. Am J Psych. 2003;160(5):857–866. doi:10.1176/appi.ajp.160.5.857
   PubMed Web of Science ®Google Scholar
• Kalia M. Dysphagia and aspiration pneumonia in patients with Alzheimer’s disease. Metabolism. 2003;52:36–38. doi:10.1016/S0026-0495(03)00300-7
   PubMed Web of Science ®Google Scholar
• Sharma P, Srivastava P, Seth A, Tripathi PN, Banerjee AG, Shrivastava SK. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Progr Neurobiol. 2019;174:53–89. doi:10.1016/j.pneurobio.2018.12.006
   PubMed Web of Science ®Google Scholar
• Franchi C, Lucca U, Tettamanti M, et al. Cholinesterase inhibitor use in Alzheimer’s disease: the EPIFARM‐Elderly Project. Pharmacoepidemiol Drug Saf. 2011;20(5):497–505. doi:10.1002/pds.2124
   PubMed Web of Science ®Google Scholar
• Khan S, Ullah H, Hussain R, et al. Synthesis, in vitro bio-evaluation, and molecular docking study of thiosemicarbazone-based isatin/bis-Schiff base hybrid analogues as effective cholinesterase inhibitors. J Mol Struct. 2023;1284:135351. doi:10.1016/j.molstruc.2023.135351
   Web of Science ®Google Scholar
• Srivastava P, Tripathi PN, Sharma P, et al. Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory. Europ J Med Chem. 2019;163:116–135. doi:10.1016/j.ejmech.2018.11.049
   PubMed Web of Science ®Google Scholar
• Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Internat J Nanomed. 2019;5541–5554. doi:10.2147/IJN.S200490
   PubMed Web of Science ®Google Scholar
• Patwardhan B. Ayurveda: the designer medicine. Indian Drugs. 2000;37(5):213–227.
   Google Scholar
• Sharma R, Kuca K, Nepovimova E, Kabra A, Rao M, Prajapati P. Traditional Ayurvedic and herbal remedies for Alzheimer’s disease: from bench to bedside. Expert Rev Neurotherap. 2019;19(5):359–374. doi:10.1080/14737175.2019.1596803
   PubMed Web of Science ®Google Scholar
• Adams M, Gmünder F, Hamburger M. Plants traditionally used in age related brain disorders—A survey of ethnobotanical literature. Journal of Ethnopharmacology. 2007;113(3):363–381. doi:10.1016/j.jep.2007.07.016
   PubMed Web of Science ®Google Scholar
• Zieneldien T, Kim J, Cao C. The multifaceted role of neuroprotective plants in Alzheimer’s Disease treatment. Geriatrics. 2022;7(2):24. doi:10.3390/geriatrics7020024
   PubMed Web of Science ®Google Scholar
• Gupta VS, Kale PP. Combinatory Approaches Targeting Cognitive Impairments and Memory Enhancement: a Review. Current Drug Targets. 2023;24(1):55–70. doi:10.2174/1389450123666220928152743
   PubMed Web of Science ®Google Scholar
• Wahid M, Ali A, Saqib F, et al. Pharmacological exploration of traditional plants for the treatment of neurodegenerative disorders. Phytoth Res. 2020;34(12):3089–3112. doi:10.1002/ptr.6742
   PubMed Web of Science ®Google Scholar
• Singh R, Bhattacharyya C, Prashar V, et al. Tinospora cordifolia: a potential neuroprotective agent against various neurodegenerative diseases. J Herbal Med. 2023;42:100775. doi:10.1016/j.hermed.2023.100775
   Web of Science ®Google Scholar
• Parihar M, Hemnani T. Alzheimer’s disease pathogenesis and therapeutic interventions. J Clin Neurosci. 2004;11(5):456–467. doi:10.1016/j.jocn.2003.12.007
   PubMed Web of Science ®Google Scholar
• Rai S Nand, Tiwari N, Singh P, et al. Therapeutic potential of vital transcription factors in Alzheimer’s and Parkinson’s disease with particular emphasis on transcription factor EB mediated autophagy. Front Neurosci. 2021;15. doi: 10.3389/fnins.2021.777347
   PubMed Web of Science ®Google Scholar
• Ramakrishna K, Nalla LV, Naresh D, et al. WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective. Diseases.2023;11(3):89. doi:10.3390/diseases11030089
   PubMed Web of Science ®Google Scholar
• Türkan F. Investigation of the toxicological and inhibitory effects of some benzimidazole agents on acetylcholinesterase and butyrylcholinesterase enzymes. Arch Physiol Biochem. 2021;127(2):97–101. doi:10.1080/13813455.2019.1618341
   PubMed Web of Science ®Google Scholar
• Korabecny J, Soukup O. Cholinesterase research. MDPI. 2021;11:1121.
   Google Scholar
• Trang A, Khandhar PB. Physiology, acetylcholinesterase; 2019.
   Google Scholar
• Kaur A, Anand C, Singh TG, Dhiman S, Babbar R. Acetylcholinesterase inhibitors: a milestone to treat neurological disorders. Plant Arch. 2019;19:1347–1359.
   Google Scholar
• Mesulam -M-M. The cholinergic innervation of the human cerebral cortex. Prog Brain Res. 2004;145:67–78.
   PubMed Web of Science ®Google Scholar
• Chen X-Q, Mobley WC. Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: converging insights from alternative hypotheses. Front Neurosci. 2019;13:451499. doi:10.3389/fnins.2019.00446
   Web of Science ®Google Scholar
• Hampel H, Mesulam MM, Cuello AC, et al. Revisiting the cholinergic hypothesis in Alzheimer’s disease: emerging evidence from translational and clinical research. Prevent Alzh Dis. 2019;6:2–15. doi:10.14283/jpad.2018.43
   PubMed Web of Science ®Google Scholar
• Mesulam MMI. Central cholinergic pathways neuroanatomy and some behavioral implications. Neurotransmitt Cort Funct. 1988;1998:237–260.
   Google Scholar
• Geula C, Dunlop SR, Ayala I, et al. Basal forebrain cholinergic system in the dementias: vulnerability, resilience, and resistance. J Neurochem. 2021;158(6):1394–1411. doi:10.1111/jnc.15471
   PubMed Web of Science ®Google Scholar
• Swaab DF, Kreier F, Lucassen PJ, Salehi A, Buijs RM. The Human Hypothalamus: Anterior Region. Elsevier; 2021.
   Google Scholar
• Tripathi PN, Srivastava P, Sharma P, et al. Biphenyl-3-oxo-1, 2, 4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorg Chem. 2019;85:82–96. doi:10.1016/j.bioorg.2018.12.017
   PubMed Web of Science ®Google Scholar
• Shrivastava SK, Nivrutti AA, Bhardwaj B, et al. Drug reposition-based design, synthesis, and biological evaluation of dual inhibitors of acetylcholinesterase and β-Secretase for treatment of Alzheimer’s disease. J Mol Struct. 2022;1262:132979. doi:10.1016/j.molstruc.2022.132979
   Web of Science ®Google Scholar
• Wright PW. Functional anatomy: types of cells/physiology. Wiley Encycl Health Psychol. 2020;2020:5–12.
   Google Scholar
• Murugan NA, Pandian CJ, Jeyaseelan JM, et al. Computational development of Alzheimer’s therapeutics and diagnostics; 2021.
   Google Scholar
• Ayvazyan NM, O’Leary VB, Dolly JO, Ovsepian SV. Neurobiology and therapeutic utility of neurotoxins targeting postsynaptic mechanisms of neuromuscular transmission. Drug Discovery Today. 2019;24(10):1968–1984. doi:10.1016/j.drudis.2019.06.012
   PubMed Web of Science ®Google Scholar
• Walczak-Nowicka ŁJ, Herbet M. Acetylcholinesterase inhibitors in the treatment of neurodegenerative diseases and the role of acetylcholinesterase in their pathogenesis. Internat J Mol Sci. 2021;22(17):9290. doi:10.3390/ijms22179290
   PubMed Web of Science ®Google Scholar
• Taha M, Sadia H, Rahim F, et al. Synthesis, biological evaluation and molecular docking study of oxindole based chalcone analogues as potent anti-Alzheimer agents. J MolStruct. 2023;1285:135530. doi:10.1016/j.molstruc.2023.135530
   Web of Science ®Google Scholar
• Bacalhau P, San Juan AA, Goth A, Caldeira AT, Martins R, Burke AJ. Insights into (S)-rivastigmine inhibition of butyrylcholinesterase (BuChE): molecular docking and saturation transfer difference NMR (STD-NMR). Bioorg Chem. 2016;67:105–109. doi:10.1016/j.bioorg.2016.06.002
   PubMed Web of Science ®Google Scholar
• Ramrao SP, Verma A, Waiker DK, Tripathi PN, Shrivastava SK. Design, synthesis, and evaluation of some novel biphenyl imidazole derivatives for the treatment of Alzheimer’s disease. J Molecul Struct. 2021;1246:131152. doi:10.1016/j.molstruc.2021.131152
   Web of Science ®Google Scholar
• Jana A, Bhattacharjee A, Das SS, et al. Molecular insights into therapeutic potentials of hybrid compounds targeting Alzheimer’s disease. Molec Neurobiol. 2022;59(6):3512–3528. doi:10.1007/s12035-022-02779-6
   PubMed Web of Science ®Google Scholar
• Premkumar T, Sajitha Lulu S. Molecular mechanisms of emerging therapeutic targets in Alzheimer’s disease: a systematic review. Neurochem J. 2022;16(4):443–455. doi:10.1134/S1819712422040183
   Google Scholar
• Khan S, Ullah H, Taha M, et al. Synthesis, DFT studies, molecular docking and biological activity evaluation of thiazole-sulfonamide derivatives as potent Alzheimer’s inhibitors. Molecules. 2023;28(2):559. doi:10.3390/molecules28020559
   PubMed Web of Science ®Google Scholar
• Hussain R, Ullah H, Rahim F, et al. Multipotent cholinesterase inhibitors for the treatment of Alzheimer’s disease: synthesis, biological analysis and molecular docking study of benzimidazole-based thiazole derivatives. Molecules. 2022;27(18):6087. doi:10.3390/molecules27186087
   PubMed Web of Science ®Google Scholar
• Jagust WJ, Teunissen CE, DeCarli C. The complex pathway between amyloid β and cognition: implications for therapy. The Lancet Neurology. 2023;22(9):847–857. doi:10.1016/S1474-4422(23)00128-X
   PubMed Web of Science ®Google Scholar
• Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem. 2009;110(4):1129–1134. doi:10.1111/j.1471-4159.2009.06181.x
   PubMed Web of Science ®Google Scholar
• Rai SN, Chaturvedi VK, Singh BK, Singh MP. Commentary: trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the Aβ42: aβ40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer’s mouse model. Front Aging Neurosci. 2020;12:219. doi:10.3389/fnagi.2020.00219
   PubMed Web of Science ®Google Scholar
• Vassar R, Bennett BD, Babu-Khan S, et al. β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286(5440):735–741. doi:10.1126/science.286.5440.735
   PubMed Web of Science ®Google Scholar
• De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry. 2001;40(35):10447–10457. doi:10.1021/bi0101392
   PubMed Web of Science ®Google Scholar
• Wu A-G, Zhou X-G, Qiao G, et al. Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases. Age Res Rev. 2021;65:101202. doi:10.1016/j.arr.2020.101202
   PubMed Web of Science ®Google Scholar
• Tan M-S, J-T Y, Jiang T, Zhu X-C, Tan L. The NLRP3 inflammasome in Alzheimer’s disease. Molec Neurobiol. 2013;48:875–882. doi:10.1007/s12035-013-8475-x
   PubMed Web of Science ®Google Scholar
• Andrade-Guerrero J, Santiago-Balmaseda A, Jeronimo-Aguilar P, et al. Alzheimer’s disease: an updated overview of its genetics. Internat J Molec Sci. 2023;24(4):3754. doi:10.3390/ijms24043754
   PubMed Web of Science ®Google Scholar
• Escamilla-Ayala A, Wouters R, Sannerud R, Annaert W. Contribution of the Presenilins in the cell biology, structure and function of γ-secretase. Paper presented at: Seminars in cell & developmental biology; 2020.
   Google Scholar
• Das N, Raymick J, Sarkar S. Role of metals in Alzheimer’s disease. Metab Brain Dis. 2021;36(7):1627–1639. doi:10.1007/s11011-021-00765-w
   PubMed Web of Science ®Google Scholar
• Davidson R, Krider RI, Borsellino P, Noorda K, Alhwayek G, Vida TA. Untangling Tau: molecular Insights into Neuroinflammation, Pathophysiology, and Emerging Immunotherapies. Curr Issu Molec Biol. 2023;45(11):8816–8839. doi:10.3390/cimb45110553
   PubMed Web of Science ®Google Scholar
• Michalicova A, Majerova P, Kovac A. Tau protein and its role in blood–brain barrier dysfunction. Front Molec Neurosci. 2020;13:570045. doi:10.3389/fnmol.2020.570045
   PubMed Web of Science ®Google Scholar
• Guha S, Johnson GV, Nehrke K. The crosstalk between pathological tau phosphorylation and mitochondrial dysfunction as a key to understanding and treating Alzheimer’s disease. Mol Neurobiol. 2020;57:5103–5120. doi:10.1007/s12035-020-02084-0
   PubMed Web of Science ®Google Scholar
• Wang L, Yin Y-L, Liu X-Z, et al. Current understanding of metal ions in the pathogenesis of Alzheimer’s disease. Translat Neurodeg. 2020;9(1):1–13. doi:10.1186/s40035-020-00189-z
   PubMed Web of Science ®Google Scholar
• Maitra S, Vincent B. Cdk5-p25 as a key element linking amyloid and tau pathologies in Alzheimer’s disease: mechanisms and possible therapeutic interventions. Life Sci. 2022;308:120986. doi:10.1016/j.lfs.2022.120986
   PubMed Web of Science ®Google Scholar
• Jiang H, Wang X, Zhang H, Chang Y, Feng M, Wu S. Loss‐of‐function mutation of serine racemase attenuates excitotoxicity by intravitreal injection of N‐methyl‐D‐aspartate. J Neuroch. 2016;136(1):186–193. doi:10.1111/jnc.13400
   PubMed Web of Science ®Google Scholar
• Pannaccione A, Piccialli I, Secondo A, et al. The Na+/Ca2+ exchanger in Alzheimer’s disease. Cell Calcium. 2020;87:102190. doi:10.1016/j.ceca.2020.102190
   PubMed Web of Science ®Google Scholar
• Kumar A, Behl T, Jamwal S, Kaur I, Sood A, Kumar P. Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder. Molec Biol Rep. 2020;47:9895–9912. doi:10.1007/s11033-020-06033-x
   PubMed Web of Science ®Google Scholar
• Allan Butterfield D. Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer’s disease brain. A review. Free Rad Res. 2002;36(12):1307–1313. doi:10.1080/1071576021000049890
   PubMed Web of Science ®Google Scholar
• Rai SN, Singh C, Singh A, Singh M, Singh BK. Mitochondrial dysfunction: a potential therapeutic target to treat Alzheimer’s disease. Mol Neurobiol. 2020;57:3075–3088. doi:10.1007/s12035-020-01945-y
   PubMed Web of Science ®Google Scholar
• Wen L-Y, Wan L, Lai J-N, et al. Increased risk of Alzheimer’s disease among patients with age-related macular degeneration: a nationwide population-based study. PLoS One. 2021;16(5):e0250440. doi:10.1371/journal.pone.0250440
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mechan Age Develop. 2001;122(9):945–962. doi:10.1016/S0047-6374(01)00249-4
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–795. doi:10.1038/nature05292
   PubMed Web of Science ®Google Scholar
• Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer’s disease. J Neurochem. 1997;68(5):2061–2069. doi:10.1046/j.1471-4159.1997.68052061.x
   PubMed Web of Science ®Google Scholar
• Ercal N, Gurer-Orhan H, Aykin-Burns N. Toxic metals and oxidative stress part I: mechanisms involved in metal-induced oxidative damage. Curr Top Med Chem. 2001;1(6):529–539. doi:10.2174/1568026013394831
   PubMedGoogle Scholar
• Teleanu DM, Niculescu A-G, Lungu II, et al. An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Internat J Molecul Sci. 2022;23(11):5938. doi:10.3390/ijms23115938
   PubMed Web of Science ®Google Scholar
• Zafar S. Chief Role of Neuroinflammation and Oxidative Stress in Brain Disorders. In: The Role of Natural Antioxidants in Brain Disorders. Springer; 2023:89–109.
   Google Scholar
• Chen X, Holtzman DM. Emerging roles of innate and adaptive immunity in Alzheimer’s disease. Immunity. 2022;55:2236–2254. doi:10.1016/j.immuni.2022.10.016
   PubMed Web of Science ®Google Scholar
• Jabeen K, Rehman K, Akash MSH. Genetic mutations of APOEε4 carriers in cardiovascular patients lead to the development of insulin resistance and risk of Alzheimer’s disease. J Biochem Mol Toxicol. 2022;36(2):e22953. doi:10.1002/jbt.22953
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Zhao N, Caulfield TR, Liu -C-C, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501–518. doi:10.1038/s41582-019-0228-7
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhao Y, Zhao B. Roles of glycogen synthase kinase 3 in Alzheimer’s disease. Curr Alzh Res. 2012;9(7):864–879. doi:10.2174/156720512802455386
   PubMed Web of Science ®Google Scholar
• Kumari S, Singh A, Singh AK, et al. Circulatory GSK-3β: blood-based biomarker and therapeutic target for Alzheimer’s disease. J Alzheim Dis. 2022;85(1):249–260. doi:10.3233/JAD-215347
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang L, Zhang C, et al. Ginsenoside Rg1 improves Alzheimer’s disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt/GSK‐3β/β‐catenin signaling pathway. Chem Biol Drug Des. 2022;99(6):884–896. doi:10.1111/cbdd.14041
   PubMed Web of Science ®Google Scholar
• Sun Y, Ai JZ, Jin X, et al. IL‐8 protects prostate cancer cells from GSK‐3β‐induced oxidative stress by activating the mTOR signaling pathway. Prostate. 2019;79(10):1180–1190. doi:10.1002/pros.23836
   PubMed Web of Science ®Google Scholar
• Barber K, Mendonca P, Soliman KF. The neuroprotective effects and therapeutic potential of the chalcone cardamonin for Alzheimer’s disease. Brain Sci. 2023;13(1):145. doi:10.3390/brainsci13010145
   PubMed Web of Science ®Google Scholar
• Parhizkar S, Holtzman DM. APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease. Paper presented at: Seminars in immunology; 2022.
   Google Scholar
• Xu L, He D, Bai Y. Microglia-mediated inflammation and neurodegenerative disease. Molecul Neurobiol. 2016;53(10):6709–6715. doi:10.1007/s12035-015-9593-4
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease—a double-edged sword. Neuron. 2002;35(3):419–432. doi:10.1016/S0896-6273(02)00794-8
   PubMed Web of Science ®Google Scholar
• Asthana A, Tripathi S, Agarwal R. A systematic review and meta-analysis of randomized control trials to check role of non-steroidal anti-inflammatory drugs as protective factor in Alzheimer disease subjects. Advan Alzheim Dis. 2023;12(1):1–16. doi:10.4236/aad.2023.121001
   Google Scholar
• Jiao X, Ashtari N, Rahimi-Balaei M, et al. Mevalonate cascade and neurodevelopmental and neurodegenerative diseases: future targets for therapeutic application. Curr Mol Pharmacol. 2017;10(2):115–140. doi:10.2174/1874467209666160112125446
   PubMed Web of Science ®Google Scholar
• Shrivastava S Kumar, Patel B K, Tripathi P Nath, Srivastava P, Sharma P, Tripathi A, Seth A and Tripathi M Kumar. (2018). Synthesis, evaluation and docking studies of some 4-thiazolone derivatives as effective lipoxygenase inhibitors. Chem. Pap., 72(11), 2769–2783. doi:10.1007/s11696-018-0520-9
   Web of Science ®Google Scholar
• Peauger L, Azzouz R, Gembus V, et al. Donepezil-based central acetylcholinesterase inhibitors by means of a “bio-oxidizable” prodrug strategy: design, synthesis, and in vitro biological evaluation. J Med Chem. 2017;60(13):5909–5926. doi:10.1021/acs.jmedchem.7b00702
   PubMed Web of Science ®Google Scholar
• Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer’s disease. Drugs. 2001;61:41–52. doi:10.2165/00003495-200161010-00005
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Intervent Aging. 2008;3(2):211–225.
   PubMed Web of Science ®Google Scholar
• Li Q, He S, Chen Y, Feng F, Qu W, Sun H. Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer’s disease. Europ J Med Chem. 2018;158:463–477. doi:10.1016/j.ejmech.2018.09.031
   PubMed Web of Science ®Google Scholar
• Gottwald MD, Rozanski RI. Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status. Expert Opin Investigational Drugs. 1999;8(10):1673–1682. doi:10.1517/13543784.8.10.1673
   PubMedGoogle Scholar
• Hopkins TJ, Rupprecht LE, Hayes MR, Blendy JA, Schmidt HD. Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacol. 2012;37(10):2310–2321. doi:10.1038/npp.2012.83
   PubMed Web of Science ®Google Scholar
• Lilienfeld S. Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002;8(2):159–176. doi:10.1111/j.1527-3458.2002.tb00221.x
   PubMedGoogle Scholar
• Gohil K. Investigation of banglenes as neurotrophic agents and development of a new fluorescent protein-based FRET pair; 2022.
   Google Scholar
• Amalraj A, Ac KV, Jude S, Kuttappan S. Galangal—Roles in nutraceuticals and functional foods. In: Herbs, Spices and Their Roles in Nutraceuticals and Functional Foods. Elsevier; 2023:95–109.
   Google Scholar
• Husain A, Al Balushi K, Akhtar MJ, Khan SA. Coumarin linked heterocyclic hybrids: a promising approach to develop multi target drugs for Alzheimer’s disease. J Molec Struct. 2021;1241:130618. doi:10.1016/j.molstruc.2021.130618
   Web of Science ®Google Scholar
• Jantrachotechatchawan C. Contribution of Cholinergic Innervation to Adult Hippocampal Neurogenesis in Dementia. King’s College London; 2019.
   Google Scholar
• Atlante A, Amadoro G, Latina V, Valenti D. Therapeutic potential of targeting mitochondria for Alzheimer’s disease treatment. J Clin Med. 2022;11(22):6742. doi:10.3390/jcm11226742
   PubMed Web of Science ®Google Scholar
• Seval N, Eaton E, Springer SA. Inpatient opioid use disorder treatment for the infectious disease physician. In: The Opioid Epidemic and Infectious Diseases. Elsevier; 2021:189–221.
   Google Scholar
• Tari PK, Parsons CG, Collingridge GL, Rammes G. Memantine: updating a rare success story in pro-cognitive therapeutics. Neuropharmacology. 2023;109737. doi:10.1016/j.neuropharm.2023.109737
   PubMed Web of Science ®Google Scholar
• Jiang N. Plasticity of Hippocampal Synaptic Transmission and Intrinsic Excitability in a Mouse Model of Alzheimer’s Disease. Université de Bordeaux; 2019.
   Google Scholar
• Kikuchi T. Is memantine effective as an NMDA receptor antagonist in adjunctive therapy for schizophrenia? Biomolecules. 2020;10(8):1134. doi:10.3390/biom10081134
   PubMed Web of Science ®Google Scholar
• Kolcheva M. Functional and pharmacological properties of GluN1/GluN2 and GluN1/GluN3 subtypes of NMDA receptors; 2023.
   Google Scholar
• Zhou Y-Q, Yang Z-L, Xu L, Li P, Y-Z H. Akebia saponin D, a saponin component from Dipsacus asper Wall, protects PC 12 cells against amyloid-β induced cytotoxicity. Cell Biol Internat. 2009;33(10):1102–1110. doi:10.1016/j.cellbi.2009.06.028
   PubMed Web of Science ®Google Scholar
• Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Internat J Alzh Dis. 2012;2012. doi:10.1155/2012/728983
   PubMedGoogle Scholar
• Mullard A. Sting of Alzheimer’s failures offset by upcoming prevention trials: three prevention trials in asymptomatic Alzheimer’s disease patients will attempt to validate the amyloid hypothesis, evaluate biomarkers and set the stage for drug approvals. Nat Rev Drug Disc. 2012;11(9):657–661. doi:10.1038/nrd3842
   PubMed Web of Science ®Google Scholar
• Ashford JW, Mahoney L, Burkett T. A role for complementary and integrative medicine in Alzheimer’s disease prevention. J Alzh Dis. 2015;48(1):13–14. doi:10.3233/JAD-150505
   PubMed Web of Science ®Google Scholar
• Huegel HM. Brain food for Alzheimer-free ageing: focus on herbal medicines. Nat Comp Therap Age Amyloidog Dis. 2015;2015:95–116.
   Google Scholar
• Li N, Zhou L, Li W, Liu Y, Wang J, He P. Protective effects of ginsenosides Rg1 and Rb1 on an Alzheimer’s disease mouse model: a metabolomics study. J Chromat. 2015;985:54–61. doi:10.1016/j.jchromb.2015.01.016
   Web of Science ®Google Scholar
• Yan S, Li Z, Li H, Arancio O, Zhang W. Notoginsenoside R1 increases neuronal excitability and ameliorates synaptic and memory dysfunction following amyloid elevation. Scien Rep. 2014;4(1):6352. doi:10.1038/srep06352
   PubMedGoogle Scholar
• Malve H. Management of Alzheimer’s disease: role of existing therapies, traditional medicines and new treatment targets. Indian J Pharmac Sci. 2017;79(1). doi:10.4172/pharmaceutical-sciences.1000195
   Web of Science ®Google Scholar
• Patwardhan B, Datta HS. Ayurveda and Brain health. In: Nutraceuticals in Brain Health and Beyond. Elsevier; 2021:441–453.
   Google Scholar
• Shown S. Efficacy of Kushmanda (Benincasa Hispida) Swarasa in Mild Cognitive Impairment (MCI) of the Elderly. India: Rajiv Gandhi University of Health Sciences; 2018.
   Google Scholar
• Nesari TM, Sanwal CS, Rath C, et al. Traditional Medicine Review; 2023.
   Google Scholar
• Barve M, Mashru M, Jagtap C, Patgiri B, Prajapati P, Prajapati PK. Therapeutic potentials of metals in ancient India: a review through Charaka Samhita. J Ayurv Integrat Med. 2011;2(2):55. doi:10.4103/0975-9476.82523
   PubMedGoogle Scholar
• Madhavi A, Savitha H. Depression-an Ayurvedic outlook. J Ayu Holistic Med. 2017;5(2):12–23.
   Google Scholar
• Prajapati KK, Pande P, Acharya P. Ayurveda view on daivavyapashraya chikitsa: A; 2022.
   Google Scholar
• Sharma R, Amin H. Rasayana Therapy: ayurvedic contribution to improve quality of life. World J Pharmacol Res Tech. 2015;4:23–33.
   Google Scholar
• Saraf P, Tripathi PN, Tripathi MK, et al. Novel 5, 6-diphenyl-1, 2, 4-triazine-3-thiol derivatives as dual COX-2/5-LOX inhibitors devoid of cardiotoxicity. Bioorg Chem. 2022;129:106147. doi:10.1016/j.bioorg.2022.106147
   PubMed Web of Science ®Google Scholar
• Dastmalchi K, Dorman HD, Vuorela H, Hiltunen R. Plants as potential sources for drug development against Alzheimer’s disease. Int J Biomed Pharm Sci. 2007;1(2):83–104.
   Google Scholar
• Simunkova M, Alwasel SH, Alhazza IM, et al. Management of oxidative stress and other pathologies in Alzheimer’s disease. Arch Toxicol. 2019;93:2491–2513. doi:10.1007/s00204-019-02538-y
   PubMed Web of Science ®Google Scholar
• Yoo K-Y, Park S-Y. Terpenoids as potential anti-Alzheimer’s disease therapeutics. Molecules. 2012;17(3):3524–3538. doi:10.3390/molecules17033524
   PubMed Web of Science ®Google Scholar
• Singh AK, Rai SN, Maurya A, et al. Therapeutic potential of phytoconstituents in management of Alzheimer’s disease. Evid Bas Complement Alternat Med. 2021;2021:1–19. doi:10.1155/2021/5578574
   Web of Science ®Google Scholar
• Ahmed F, Chandra J, Urooj A, Rangappa K. In vitro antioxidant and anticholinesterase activity of Acorus calamus and Nardostachys jatamansi rhizomes. J Phar Res. 2009;2(5):830–883.
   Google Scholar
• Vohora S, Shah SA, Dandiya P. Central nervous system studies on an ethanol extract of Acorus calamus rhizomes. J Ethnopharmacol. 1990;28(1):53–62. doi:10.1016/0378-8741(90)90065-2
   PubMed Web of Science ®Google Scholar
• Sharma V, Sharma R, Gautam DS, Kuca K, Nepovimova E, Martins N. Role of Vacha (Acorus calamus Linn.) in neurological and metabolic disorders: evidence from ethnopharmacology, phytochemistry, pharmacology and clinical study. J Clin Med. 2020;9(4):1176. doi:10.3390/jcm9041176
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acetylcholinesterase inhibitors from plants. Phytomedicine. 2007;14(4):289–300. doi:10.1016/j.phymed.2007.02.002
   PubMed Web of Science ®Google Scholar
• Li D, Ma J, Wei B, Gao S, Lang Y, Wan X. Effectiveness and safety of ginkgo biloba preparations in the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2023;15:1124710. doi:10.3389/fnagi.2023.1124710
   PubMed Web of Science ®Google Scholar
• Assumpção CF, Bachiega P, Morzelle MC, et al. Characterization, antioxidant potential and cytotoxic study of mangaba fruits. Ciência Rural. 2014;44:1297–1303. doi:10.1590/0103-8478cr20130855
   Web of Science ®Google Scholar
• Choi BW, Lee HS, Shin HC, Lee BH. Multifunctional activity of polyphenolic compounds associated with a potential for Alzheimer’s disease therapy from Ecklonia cava. Phytoth Res. 2015;29(4):549–553. doi:10.1002/ptr.5282
   PubMed Web of Science ®Google Scholar
• El-Hawary SS, Fathy FI, Sleem AA, Morsy FA, Khadar MS, Mansour MK. Anticholinesterase activity and metabolite profiling of Syagrus romanzoffiana (Cham.) Glassman leaves and fruits via UPLC–QTOF–PDA–MS. Nat Prod Res. 2021;35(10):1671–1675. doi:10.1080/14786419.2019.1622113
   PubMed Web of Science ®Google Scholar
• Imran M, Ullah F, Ayaz M, et al. Anticholinesterase and antioxidant potentials of Nonea micrantha Bioss. & Reut along with GC-MS analysis. BMC Complement Alternat Med. 2017;17(1):1–12. doi:10.1186/s12906-017-2004-9
   PubMedGoogle Scholar
• Kaur N, Sarkar B, Gill I, et al. Indian herbs and their therapeutic potential against Alzheimer’s disease and other neurological disorders. Neuroprot Effe Phytochem Neurolog Dis. 2017;2017:79–112.
   Google Scholar
• Panossian A, Seo E-J, Efferth T. Effects of anti-inflammatory and adaptogenic herbal extracts on gene expression of eicosanoids signaling pathways in isolated brain cells. Phytomedicine. 2019;60:152881. doi:10.1016/j.phymed.2019.152881
   PubMed Web of Science ®Google Scholar
• Khojah H, Edrada-Ebel R. P43 the isolation and purification of bioactive metabolites from Ficus carica and their neuroprotective effects in Alzheimer’s disease. Biochem Pharmacol. 2017;139:140. doi:10.1016/j.bcp.2017.06.044
   Web of Science ®Google Scholar
• Chen H-Y, Yen G-C. Antioxidant activity and free radical-scavenging capacity of extracts from guava (Psidium guajava L.) leaves. Food Chem. 2007;101(2):686–694. doi:10.1016/j.foodchem.2006.02.047
   Web of Science ®Google Scholar
• Aly SH, Eldahshan OA, Al-Rashood ST, et al. Chemical constituents, antioxidant, and enzyme inhibitory activities supported by in-silico study of n-hexane extract and essential oil of guava leaves. Molecules. 2022;27(24):8979. doi:10.3390/molecules27248979
   PubMed Web of Science ®Google Scholar
• Kamran M, Kousar R, Ullah S, et al. Taxonomic distribution of medicinal plants for Alzheimer’s Disease: a cue to novel drugs. Internat J Alzh Dis. 2020;2020:1–15. doi:10.1155/2020/7603015
   Google Scholar
• Choi BW, Ryu G, Park SH, et al. Anticholinesterase activity of plastoquinones from Sargassum sagamianum: lead compounds for Alzheimer’s disease therapy. Phytoth Res. 2007;21(5):423–426. doi:10.1002/ptr.2090
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Banerjee N, Chatterjee S, et al. Role of turmeric in management of different non-communicable diseases. World J Pharm Pharmac Sci. 2017;6(7):1767–1778.
   Google Scholar
• Uddin MJ, Alam MN, Biswas K, Rahman MA. In vitro antioxidative and cholinesterase inhibitory properties of Thunbergia grandiflora leaf extract. Cogent Food Agricult. 2016;2(1):1256929. doi:10.1080/23311932.2016.1256929
   Google Scholar
• Penido AB, De Morais SM, Ribeiro AB, et al. Medicinal plants from northeastern Brazil against Alzheimer’s disease. Evid Bas Complement Altern Med. 2017;2017. doi:10.1155/2017/1753673
   PubMed Web of Science ®Google Scholar
• Panche AN, Chandra S, Diwan A. Multi-target β-protease inhibitors from Andrographis paniculata: in silico and in vitro studies. Plants. 2019;8(7):231. doi:10.3390/plants8070231
   Google Scholar
• Sobhani R, Pal AK, Bhattacharjee A, Mitra S, Aguan K. Screening indigenous medicinal plants of Northeast India for their anti-Alzheimer’s properties. Pharmacog J. 2017;9(1):1.
   Google Scholar
• Cioanca O, Hritcu L, Mihasan M, Trifan A, Hancianu M. Inhalation of coriander volatile oil increased anxiolytic–antidepressant-like behaviors and decreased oxidative status in beta-amyloid (1–42) rat model of Alzheimer’s disease. Physiol Behav. 2014;131:68–74. doi:10.1016/j.physbeh.2014.04.021
   PubMed Web of Science ®Google Scholar
• Zarmouh NO, Messeha SS, Elshami FM, Soliman KF. Natural products screening for the identification of selective monoamine oxidase-B inhibitors. Europ J Med Plant. 2016;15(1):1–16. doi:10.9734/EJMP/2016/26453
   Google Scholar
• Sabzehzari M, Naghavi MR, Bozari M, Orafai HM, Johnston TP, Sahebkar A. Pharmacological and therapeutic aspects of plants from the genus Ferula: a comprehensive review. Mini Rev Med Chem. 2020;20(13):1233–1257. doi:10.2174/1389557520666200505125618
   PubMed Web of Science ®Google Scholar
• Sithisarn P, Jarikasem S. Antioxidant activity of Acanthopanax trifoliatus. Med Princip Pract. 2009;18(5):393–398. doi:10.1159/000226294
   PubMed Web of Science ®Google Scholar
• Feroz F, Naeem I, Nawaz SA, Khan N, Khan MR, Choudhary MI. New pregnane-type steroidal alkaloids from Sarcococca saligna and their cholinesterase inhibitory activity. Steroids. 2004;69(11–12):735–741. doi:10.1016/j.steroids.2004.03.016
   PubMed Web of Science ®Google Scholar
• Parveen S, Farooq A, Farooq A, Choudhary MI, Choudhary MI. Acetyl and butyrylcholinesterase-inhibiting triterpenoid alkaloids from Buxus papillosa. Phytochemistry. 2001;58(6):963–968. doi:10.1016/S0031-9422(01)00332-6
   PubMed Web of Science ®Google Scholar
• Hostettmann K, Borloz A, Urbain A, Marston A. Natural product inhibitors of acetylcholinesterase. Curr Org Chem. 2006;10(8):825–847. doi:10.2174/138527206776894410
   Web of Science ®Google Scholar
• Chen Y, Zhang J, Zhang B, Gong C-X. Targeting insulin signaling for the treatment of Alzheimer’s disease. Curr Top Med Chem. 2016;16(5):485–492. doi:10.2174/1568026615666150813142423
   PubMed Web of Science ®Google Scholar
• Batista ÂG, Ferrari AS, da Cunha DC, et al. Polyphenols, antioxidants, and antimutagenic effects of Copaifera langsdorffii fruit. Food Chemistry. 2016;197:1153–1159. doi:10.1016/j.foodchem.2015.11.093
   PubMed Web of Science ®Google Scholar
• Kaur N, Sarkar B, Gill I, et al. Indian herbs and their therapeutic potential against Alzheimer’s disease: what makes them special? Neuroprot Eff Phytochem Neurolog Dis. 2016;2016:1.
   Google Scholar
• Damodaran T, Tan BWL, Liao P, Ramanathan S, Lim GK, Hassan Z. Clitoria ternatea L. root extract ameliorated the cognitive and hippocampal long-term potentiation deficits induced by chronic cerebral hypoperfusion in the rat. J Ethnopharmacol. 2018;224:381–390. doi:10.1016/j.jep.2018.06.020
   PubMed Web of Science ®Google Scholar
• Vladimir-Knežević S, Blažeković B, Kindl M, Vladić J, Lower-Nedza AD, Brantner AH. Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family. Molecules. 2014;19(1):767–782. doi:10.3390/molecules19010767
   PubMed Web of Science ®Google Scholar
• Oskouie AA, Yekta RF, Tavirani MR, Kashani MS, Goshadrou F. Lavandula angustifolia effects on rat models of Alzheimer’s disease through the investigation of serum metabolic features using NMR metabolomics. Avic J Med Biotech. 2018;10(2):83.
   PubMedGoogle Scholar
• Soheili M, Tavirani MR, Salami M. Lavandula angustifolia extract improves deteriorated synaptic plasticity in an animal model of Alzheimer’s disease. Iranian J Bas Med Sci. 2015;18(11):1147.
   PubMed Web of Science ®Google Scholar
• Rychlik M. Quantification of free coumarin and its liberation from glucosylated precursors by stable isotope dilution assays based on liquid chromatography− tandem mass spectrometric detection. J Agricult Food Chem. 2008;56(3):796–801. doi:10.1021/jf0728348
   PubMed Web of Science ®Google Scholar
• Rafii M, Walsh S, Little J, et al. A Phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389–1394. doi:10.1212/WNL.0b013e318216eb7b
   PubMed Web of Science ®Google Scholar
• Calderón AI, Simithy-Williams J, Sanchez R, Espinosa A, Valdespino I, Gupta MP. Lycopodiaceae from Panama: a new source of acetylcholinesterase inhibitors. Natural Prod Res. 2013;27(4–5):500–505. doi:10.1080/14786419.2012.701217
   PubMed Web of Science ®Google Scholar
• Howes M-JR, Fang R, Houghton PJ. Effect of Chinese herbal medicine on Alzheimer’s disease. Internat Rev Neurobiol. 2017;135:29–56.
   PubMed Web of Science ®Google Scholar
• Dwivedi C, Chandrakar K, Singh V, et al. Indian herbal medicines used for treatment of dementia: an overview. Internat J Pharmacog. 2014;1(9):353–371.
   Google Scholar
• Limpeanchob N, Jaipan S, Rattanakaruna S, Phrompittayarat W, Ingkaninan K. Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J Ethnopharmacol. 2008;120(1):112–117. doi:10.1016/j.jep.2008.07.039
   PubMed Web of Science ®Google Scholar
• Sehgal N, Gupta A, Valli RK, et al. Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proceed Nat Acad Sci. 2012;109(9):3510–3515. doi:10.1073/pnas.1112209109
   PubMed Web of Science ®Google Scholar
• Kim B-W, Koppula S, Park S-Y, et al. Attenuation of inflammatory-mediated neurotoxicity by Saururus chinensis extract in LPS-induced BV-2 microglia cells via regulation of NF-κB signaling and anti-oxidant properties. BMC Complement Altern Med. 2014;14:1–10. doi:10.1186/1472-6882-14-502
   PubMed Web of Science ®Google Scholar
• Sung SH, Kwon SH, Cho NJ, Kim YC. Hepatoprotective flavonol glycosides of Saururus chinensis herbs. Phytoth Res. 1997;11(7):500–503. doi:10.1002/(SICI)1099-1573(199711)11:7<500::AID-PTR139>3.0.CO;2-P
   Web of Science ®Google Scholar
• Wang B. Chemical characterization and ameliorating effect of polysaccharide from Chinese jujube on intestine oxidative injury by ischemia and reperfusion. Internat J Biolog Macromolec. 2011;48(3):386–391. doi:10.1016/j.ijbiomac.2010.12.005
   PubMed Web of Science ®Google Scholar
• Hosseini M, Mohammadpour T, Karami R, Rajaei Z, Reza Sadeghnia H, Soukhtanloo M. Effects of the hydro-alcoholic extract of Nigella sativa on scopolamine-induced spatial memory impairment in rats and its possible mechanism. Chin J Integ Med. 2015;21:438–444. doi:10.1007/s11655-014-1742-5
   PubMed Web of Science ®Google Scholar
• Khazdair MR. The protective effects of Nigella sativa and its constituents on induced neurotoxicity. J Toxicol. 2015;2015. doi:10.1155/2015/841823
   PubMedGoogle Scholar
• Cascella M, Bimonte S, Barbieri A, et al. Dissecting the potential roles of nigella sativa and its constituent thymoquinone on the prevention and on the progression of Alzheimer’s disease. Front Aging Neurosci. 2018;10:16. doi:10.3389/fnagi.2018.00016
   PubMed Web of Science ®Google Scholar
• Choudhary S, Kumar P, Malik J. Plants and phytochemicals for Huntington’s disease. Pharmacog Rev. 2013;7(14):81. doi:10.4103/0973-7847.120505
   PubMedGoogle Scholar
• Mir NT, Saleem U, Anwar F, et al. Lawsonia Inermis markedly improves cognitive functions in animal models and modulate oxidative stress markers in the brain. Medicina. 2019;55(5):192. doi:10.3390/medicina55050192
   PubMed Web of Science ®Google Scholar
• Wang Y-H, Du G-H. Ginsenoside Rg1 inhibits β-secretase activity in vitro and protects against Aβ-induced cytotoxicity in PC12 cells. J Asian Nat Prod Res. 2009;11(7):604–612. doi:10.1080/10286020902843152
   PubMed Web of Science ®Google Scholar
• Qu J, Xu N, Zhang J, Geng X, Zhang R. Panax notoginseng saponins and their applications in nervous system disorders: a narrative review. Ann Translati Med. 2020;8(22):1525–1525. doi:10.21037/atm-20-6909
   PubMed Web of Science ®Google Scholar
• Bäurle P, Suter A, Wormstall H. Safety and effectiveness of a traditional ginkgo fresh plant extract–results from a clinical trial. Complem Med Res. 2009;16(3):156–161. doi:10.1159/000213167
   Google Scholar
• Isah T. Rethinking Ginkgo biloba L.: medicinal uses and conservation. Pharmacog Rev. 2015;9(18):140. doi:10.4103/0973-7847.162137
   PubMedGoogle Scholar
• Tao Y, Chen L, Yan J. Traditional uses, processing methods, phytochemistry, pharmacology and quality control of Dipsacus asper Wall. ex CB Clarke: a review. J Ethnopharmacol. 2020;258:112912. doi:10.1016/j.jep.2020.112912
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Tabuchi M, Yamaguchi T, et al. A traditional medicinal herb Paeonia suffruticosa and its active constituent 1, 2, 3, 4, 6‐penta‐O‐galloyl‐β‐d‐glucopyranose have potent anti‐aggregation effects on Alzheimer’s amyloid β proteins in vitro and in vivo. J Neuroch. 2009;109(6):1648–1657. doi:10.1111/j.1471-4159.2009.06069.x
   PubMed Web of Science ®Google Scholar
• Lv J, Jia H, Jiang Y, et al. Tenuifolin, an extract derived from tenuigenin, inhibits amyloid‐β secretion in vitro. Acta Physiol. 2009;196(4):419–425. doi:10.1111/j.1748-1716.2009.01961.x
   PubMed Web of Science ®Google Scholar
• Yin Y, Huang L, Liu Y, et al. Effect of tanshinone on the levels of nitric oxide synthase and acetylcholinesterase in the brain of Alzheimer’s disease rat model. Clin Investigat Med;2008. E248–E257. doi:10.25011/cim.v31i5.4871
   PubMed Web of Science ®Google Scholar
• Wang R-N, Zhao H-C, Huang J-Y, et al. Challenges and strategies in progress of drug delivery system for traditional Chinese medicine Salviae Miltiorrhizae Radix et Rhizoma (Danshen). Chin Herbal Med. 2021;13(1):78–89. doi:10.1016/j.chmed.2020.08.001
   PubMed Web of Science ®Google Scholar
• Eckert GP. Traditional used plants against cognitive decline and Alzheimer disease. Front Pharmacol. 2010;1:138. doi:10.3389/fphar.2010.00138
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Iwasaki K, Furukawa K, et al. Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation effects on Alzheimer’s β‐amyloid proteins. J Neurosci Res. 2006;84(2):427–433. doi:10.1002/jnr.20891
   PubMed Web of Science ®Google Scholar
• Xian Y-F, Lin Z-X, Zhao M, Mao -Q-Q, S-P I, Che C-T. Uncaria rhynchophylla ameliorates cognitive deficits induced by D-galactose in mice. Planta Med. 2011;77(18):1977–1983. doi:10.1055/s-0031-1280125
   PubMed Web of Science ®Google Scholar
• Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer’s disease model. J Ethnopharmac. 2010;127(1):26–31. doi:10.1016/j.jep.2009.09.056
   PubMed Web of Science ®Google Scholar
• Banerjee S, Anand U, Ghosh S, et al. Bacosides from Bacopa monnieri extract: an overview of the effects on neurological disorders. Phytoth Res. 2021;35(10):5668–5679. doi:10.1002/ptr.7203
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi A, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo‐controlled trial. J Clin Pharm Therapeut. 2003;28(1):53–59. doi:10.1046/j.1365-2710.2003.00463.x
   PubMed Web of Science ®Google Scholar
• Ghorbani A, Esmaeilizadeh M. Pharmacological properties of Salvia officinalis and its components. J Tradit Complem Med. 2017;7(4):433–440. doi:10.1016/j.jtcme.2016.12.014
   PubMedGoogle Scholar
• Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi A, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psych. 2003;74(7):863–866. doi:10.1136/jnnp.74.7.863
   PubMed Web of Science ®Google Scholar
• Soodi M, Naghdi N, Hajimehdipoor H, Choopani S, Sahraei E. Memory-improving activity of Melissa officinalis extract in naïve and scopolamine-treated rats. Res Pharmac Sci. 2014;9(2):107.
   PubMedGoogle Scholar
• Vasudevan M, Parle M. Antiamnesic potential of Murraya koenigii leaves. Phytoth Res. 2009;23(3):308–316. doi:10.1002/ptr.2620
   PubMed Web of Science ®Google Scholar
• Tan MA, Sharma N, An SSA. Multi-Target approach of Murraya koenigii leaves in treating neurodegenerative diseases. Pharmaceuticals. 2022;15(2):188. doi:10.3390/ph15020188
   Web of Science ®Google Scholar
• Kim DH, Hyun SK, Yoon BH, et al. Gluco-obtusifolin and its aglycon, obtusifolin, attenuate scopolamine-induced memory impairment. J Pharmacol Sci. 2009;111(2):110–116. doi:10.1254/jphs.08286FP
   PubMed Web of Science ®Google Scholar
• Kim DH, Yoon BH, Kim Y-W, et al. The seed extract of Cassia obtusifolia ameliorates learning and memory impairments induced by scopolamine or transient cerebral hypoperfusion in mice. J Pharmacol Sci. 2007;105(1):82–93. doi:10.1254/jphs.FP0061565
   PubMed Web of Science ®Google Scholar
• Dhanasekaran M, Holcomb LA, Hitt AR, et al. Centella asiatica extract selectively decreases amyloid β levels in hippocampus of Alzheimer’s disease animal model. Phytoth Res. 2009;23(1):14–19. doi:10.1002/ptr.2405
   PubMed Web of Science ®Google Scholar
• Lai CS-W, Yu M-S, Yuen W-H, K-F S, Zee S-Y, Chang R-C-C. Antagonizing β-amyloid peptide neurotoxicity of the anti-aging fungus Ganoderma lucidum. Brain Res. 2008;1190:215–224. doi:10.1016/j.brainres.2007.10.103
   PubMed Web of Science ®Google Scholar
• Joshi H, Parle M. Antiamnesic effects of Desmodium gangeticum in mice. Yakugaku Zasshi. 2006;126(9):795–804. doi:10.1248/yakushi.126.795
   PubMed Web of Science ®Google Scholar
• M-S Y, Leung SK-Y, Lai S-W, et al. Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against β-amyloid peptide neurotoxicity. Experim Gerontol. 2005;40(8–9):716–727. doi:10.1016/j.exger.2005.06.010
   PubMed Web of Science ®Google Scholar
• Tabuchi M, Yamaguchi T, Iizuka S, Imamura S, Ikarashi Y, Kase Y. Ameliorative effects of yokukansan, a traditional Japanese medicine, on learning and non-cognitive disturbances in the Tg2576 mouse model of Alzheimer’s disease. J Ethnoph. 2009;122(1):157–162. doi:10.1016/j.jep.2008.12.010
   PubMed Web of Science ®Google Scholar
• Tohda C, Tamura T, Komatsu K. Repair of amyloid β (25–35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to. Brain Res. 2003;990(1–2):141–147. doi:10.1016/S0006-8993(03)03449-8
   PubMed Web of Science ®Google Scholar
• Saxena G, Singh SP, Pal R, Singh S, Pratap R, Nath C. Gugulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol Biochemist Behav. 2007;86(4):797–805. doi:10.1016/j.pbb.2007.03.010
   PubMed Web of Science ®Google Scholar
• Gharibi A, Khalili M, Kiasalari Z, Hoseinirad M. The effect of Zingiber officinalis L. on learning and memory in rats. J Bas Clin Pathophysiol. 2013;2:2013–2014.
   Google Scholar
• Vasudevan M, Parle M. Memory enhancing activity of Anwala churna (Emblica officinalis Gaertn.): an Ayurvedic preparation. Physiol Behav. 2007;91(1):46–54. doi:10.1016/j.physbeh.2007.01.016
   PubMed Web of Science ®Google Scholar
• Singh H, Dhawan B. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn.(Brahmi). Indian J Pharmacol. 1997;29(5):359.
   Google Scholar
• Sharma R, Amin H, Prajapati P, Ruknuddin G. Therapeutic Vistas of Guduchi (Tinospora cordifolia): a medico-historical memoir. J Res Educ Ind Med. 2014;20:113–128.
   Google Scholar
• Rajakrishnan V, Viswanathan P, Rajasekharan K, Menon VP. Neuroprotective role of curcumin from Curcuma longa on ethanol‐induced brain damage. Phytoth Res. 1999;13(7):571–574. doi:10.1002/(SICI)1099-1573(199911)13:7<571::AID-PTR494>3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Karkada G, Shenoy K, Halahalli H, Karanth K. Nardostachys jatamansi extract prevents chronic restraint stress-induced learning and memory deficits in a radial arm maze task. J Nat Sci, Bio Med. 2012;3(2):125. doi:10.4103/0976-9668.101879
   PubMedGoogle Scholar
• Vasundhara S, Hafsa A, Rajiv G. Memory enhancing effects of Ficus carica leaves in hexane extract on interoceptive behavioral models. Asian J Pharm Clin Res. 2013;6(3):109–113.
   Google Scholar
• Pramodinee D, Mahesh M, Niranjan D, Sankpala S. Memory enhancing activity of Cissampelos papiera in mice. Int J Pharm Sci. 2011;3:206–211.
   Google Scholar
• Roy C, Ghosh T, Guha D. The antioxidative role of Benincasa hispida on colchicine induced experimental rat model of Alzheimer’s disease. Biogenic Amines. 2007;21(1/2):1.
   Google Scholar
• Jyothi P, Kumara S. Central nervous system protection by Catharanthus roseus leaf extract in streptozotocin-induced diabetes in rat brain. J Pharmacog. 2012;3(2):63–66.
   Google Scholar
• Carlini E. Plants and the central nervous system. Pharmacol Biochem Behav. 2003;75(3):501–512. doi:10.1016/S0091-3057(03)00112-6
   PubMed Web of Science ®Google Scholar
• Pradeep S, Prabhuswaminath SC, Reddy P, et al. Anticholinesterase activity of Areca Catechu: in vitro and in silico green synthesis approach in search for therapeutic agents against Alzheimer’s disease. Fronti Pharmacol. 2022;13:1044248. doi:10.3389/fphar.2022.1044248
   PubMed Web of Science ®Google Scholar
• Kashyap P, Muthusamy K, Niranjan M, Trikha S, Kumar S. Sarsasapogenin: a steroidal saponin from Asparagus racemosus as multi target directed ligand in Alzheimer’s disease. Steroids. 2020;153:108529. doi:10.1016/j.steroids.2019.108529
   PubMed Web of Science ®Google Scholar
• Rai K, Murthy K, Karanth K, Nalini K, Rao M, Srinivasan K. Clitoria ternatea root extract enhances acetylcholine content in rat hippocampus. Fitoterapia. 2002;73(7–8):685–689. doi:10.1016/S0367-326X(02)00249-6
   PubMed Web of Science ®Google Scholar
• Cambay Z, Baydas G, Tuzcu M, Bal R. Pomegranate (Punica granatum L.) flower improves learning and memory performances impaired by diabetes mellitus in rats. Acta Physiol Hung. 2011;98(4):409–420. doi:10.1556/APhysiol.98.2011.4.4
   PubMedGoogle Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Therap. 1998;20(4):634–647. doi:10.1016/S0149-2918(98)80127-6
   PubMed Web of Science ®Google Scholar
• Razay G, Wilcock GK. Galantamine in Alzheimer’s disease. Exp Rev Neurotherap. 2008;8(1):9–17. doi:10.1586/14737175.8.1.9
   PubMedGoogle Scholar
• Maelicke A, Hoeffle-Maas A, Ludwig J, et al. Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosc. 2010;40:135–137. doi:10.1007/s12031-009-9269-5
   PubMed Web of Science ®Google Scholar
• Williams P, Sorribas A, Howes M-JR. Natural products as a source of Alzheimer’s drug leads. Nat Prod Rep. 2011;28(1):48–77. doi:10.1039/c0np00027b
   PubMed Web of Science ®Google Scholar
• Ha GT, Wong RK, Zhang Y. Huperzine a as potential treatment of Alzheimer’s disease: an assessment on chemistry, pharmacology, and clinical studies. Chem Biodiv. 2011;8(7):1189–1204. doi:10.1002/cbdv.201000269
   PubMed Web of Science ®Google Scholar
• Nishteswar K, Joshi H, Karra RD. Role of indigenous herbs in the management of Alzheimer’s disease. Anci Sci Life. 2014;34(1):3. doi:10.4103/0257-7941.150763
   PubMedGoogle Scholar
• Amin H, Sharma R. Nootropic efficacy of satvavajaya chikitsa and ayurvedic drug therapy: a comparative clinical exposition. Internat J Yoga. 2015;8(2):109. doi:10.4103/0973-6131.158473
   PubMedGoogle Scholar